Cannabinoids in the Treatment of Somatic Inflammatory Pain | cannabisMD

Cannabinoids in the Treatment of Somatic Inflammatory Pain

Cannabinoids Treatment of Somatic Inflammatory Pain

The anti-hyperalgesic actions of the cannabinoid anandamide and the putative CB2 receptor agonist palmitoylethanolamide in visceral and somatic inflammatory pain

A cannabinoid is one of a great collection of complex chemical compounds that naturally occur in the body and operates on major cannabinoid receptors in cells that mediates neurotransmitter release in the brain. Cannabinoids for these receptors include the endocannabinoid system, that are produced in the body by animals, the phytocannabinoids in cannabis and some other plants, and synthetic cannabinoids. The main cannabinoid is the phytocannabinoid tetrahydrocannabinol (THC), the primary psychoactive chemical in cannabis. Cannabidiol (CBD) is another main constituent of the plant and produces a non psychotic effect. This paper will review the cannabinoid anandamide and it’s potential in treating visceral and reducing inflammation.

Main Points

  • Cannabinoid have a good anti inflammatory potential
  • Cannabinoids activate a therapeutic feeling in rats

Cannabinoid have a good anti inflammatory potential

This research assessed the impacts of two N-acylethanolamides in existing rat subjects of visceral and somatic inflammatory pain. The therapeutic impacts of the cannabinoid anandamide and the presumed CB2 agonist palmitoylethanolamide were experimented in a subject of continued visceral pain (turpentine inflammation of the urinary bladder). Both anandamide (at a dose of 25 mg/kg) and palmitoylethanolamide (at doses of 10–30 mg/kg) had to ability to attenuate the viscero-visceral hyperreflexia (VVH) induced by inflammation of the urinary bladder. The impacts of the same chemicals on the behavioural reactions to subcutaneous formalin injection were evaluated. The characteristic biphasic reaction was seen in mediated animals. Anandamide (dose range 5–25 mg/kg) and palmitoylethanolamide (dose range 5–10 mg/kg) both decreased the second phase of the reaction. The conclusions confirm the therapeutic possibility of endogenous cannabinoids at cannabinoid receptor sites. The antinociceptive impact of the presumed CB2 receptor agonist, palmitoylethanolamide, is specifically intriguing since it is known to be a peripherally controlled impact. This evaluation may be taken advantage of to separate central psychotropic impacts from peripheral therapeutic ability of the cannabinoids, under inflammatory situations.

Cannabinoids activate a therapeutic feeling in rats

Overall, these discoveries are that the cannabinoid ANA and the presumed CB2 agonist palmitoylethanolamide have the ability to reverse both the VVH (but not the tissue oedema) facilitated by turpentine instillation into the bladder and the nociceptive actions hosted by s.c. formalin injection in the centre of the paw of the rat. Since the size of available evidence lends a hand to the fact that palmitoylethanolamide is a CB2 receptor agonist and is exempt of functioning at brain CB1 cannabinoid receptors, it may be potentially viable to separate the undoubtable central impacts of cannabinoids from the peripheral therapeutic impacts during inflammation, thus paving the path for the development of applicable cannabinoid therapeutic drugs exempt of psychotropic impacts. It has also been handed in that this may also be a reachable goal using the impacts of cannabinoids in the treatment of multiple sclerosis, inflammatory bowel disease, heart disease, rheumatoid arthritis, long term chronic inflammation and neuropathic pain.

3640

Leave a Reply

Your email address will not be published. Required fields are marked *